A controversial Indian patents bill could threaten the lives of millions of people worldwide living with HIV-AIDS and cancer by banning companies from producing cheap copies of brand name drugs.Global health activists and groups representing th
Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, today announced that it has had an additional European patent granted by the Europe
Vical Incorporated announced today the issuance of two Canadian patents on the company's core technology, which involves direct administration of polynucleotide genetic material such as DNA or RNA.
More than $20 billion in major cardiovascular drug revenues will be exposed to patent expiration in the next three to five years, according to a report by business intelligence firm Cutting Edge Information. The report, entitled "Cardiovascular Marketi
A California federal court has ruled that GlaxoSmithKline's (GSK) Chief Executive Officer, Jean-Pierre Garnier, must answer further questions in a deposition in a patent piracy lawsuit brought against the British drug giant over GSK's patent for AZT (R
Australian biotech Peplin Limited has announced today that the US Patent and Trademark Office had granted Peplin a patent covering the use of its macrocyclic anti-cancer compounds to stimulate the immu
ARC Pharmaceuticals Inc. (ARC) announced today that The University of British Columbia (UBC) has been granted a new US patent entitled "Pharmaceutical
Maxim Pharmaceuticals have announced the United States Patent and Trademark Office issued U.S. patent number 6,828,091 B2, entitled "Method of Identifying Immunosuppressive Agents." The patent c
Generex Biotechnology announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen Expres
Bionomics Limited announced today that it has filed further patent applications in key markets (including the US) relating to its proprietary cancer drug target BNO69.The role of BNO69 as
The Stem Cell Delivery Device, for which the utility patent was filed, is a system for the regeneration of cardiac muscle post myocardial infarction. This apparatus is designed for the targeted delivery of peripheral blood-derived autologous adult stem cells to diseased tissue for the purpose of regenerating healthy functional tissue. The Company believes that adult stem cells have tremendous potential to promote the regeneration of dead or diseased cardiac tissue.
"We are pleased that research continues to show that adult stem cells provide significant promise for restorative therapies," said LifeStem President Dan Fulkerson. "LifeStem is committed to its plan to continue to work with adult stem cells and to further develop our delivery of stem cells into diseased heart tissue through our proprietary system," said Mr. Fulkerson. "The Company continues to move forward expeditiously in the stem cell arena, which holds the promise of conquering some of mankind's most dreaded diseases."
Current scientific data supports the contention that stem cells hold huge promise for the treatment, cure and possible prevention of numerous diseases including heart disease and Parkinson's Disease, as well as spinal cord injuries. Recent data has indicated that if adult autologous (one's own) stem cells are reintroduced to the donor, it could provide advantages similar to embryonic stem cells without the risk of rejection.
http://www.calbatech.com/